8 years of historical data (2018–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AbCellera Biologics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.0B | $862M | $1.7B | $3.2B | $4.6B | $10.6B | — | — |
| Enterprise Value | $1.1B | $1.0B | $771M | $1.6B | $2.9B | $4.1B | $10.0B | — | — |
| P/E Ratio → | -7.37 | — | — | — | 20.26 | 29.79 | 89.42 | — | — |
| P/S Ratio | 14.44 | 13.60 | 29.91 | 43.42 | 6.57 | 12.13 | 45.41 | — | — |
| P/B Ratio | 1.12 | 1.06 | 0.82 | 1.43 | 2.59 | 4.44 | 12.75 | — | — |
| P/FCF | — | — | — | — | 15.58 | 24.45 | 1320.74 | — | — |
| P/OCF | — | — | — | — | 11.50 | 18.61 | 466.65 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.72 | 26.75 | 41.95 | 5.94 | 10.97 | 42.89 | — | — |
| EV / EBITDA | — | — | — | — | 11.56 | 18.57 | 62.00 | — | — |
| EV / EBIT | — | — | — | — | 12.71 | 18.55 | 60.85 | — | — |
| EV / FCF | — | — | — | — | 14.09 | 22.11 | 1247.47 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
AbCellera Biologics Inc. earns an operating margin of -289.0%. Operating margins have expanded from -623.8% to -289.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -14.5% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 86.3% | 87.9% | 88.4% | 100.0% | 34.3% |
| Operating Margin | -289.0% | -289.0% | -1091.7% | -623.8% | 44.6% | 54.5% | 66.9% | -35.5% | -8.5% |
| Net Profit Margin | -194.9% | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% | -19.0% | 3.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.5% | -14.5% | -14.7% | -12.3% | 14.0% | 16.5% | 28.3% | -20.2% | 2.7% |
| ROA | -14.7% | -14.7% | -11.4% | -9.7% | 11.1% | 13.2% | 23.1% | -9.8% | 1.4% |
| ROIC | -16.8% | -16.8% | -22.9% | -17.6% | 21.4% | 36.8% | 92.6% | -43.5% | — |
| ROCE | -23.5% | -23.5% | -23.7% | -17.0% | 16.5% | 19.5% | 34.0% | -26.9% | -5.0% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $9M ($137M total debt minus $129M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 0.06 | 0.07 | 0.07 | 0.04 | 0.01 | 0.67 | 0.30 |
| Debt / EBITDA | — | — | — | — | 0.33 | 0.18 | 0.04 | — | 20.81 |
| Net Debt / Equity | — | 0.01 | -0.09 | -0.05 | -0.25 | -0.43 | -0.71 | -0.06 | -0.60 |
| Net Debt / EBITDA | — | — | — | — | -1.22 | -1.97 | -3.64 | — | -42.32 |
| Debt / FCF | — | — | — | — | -1.49 | -2.34 | -73.26 | — | — |
| Interest Coverage | — | — | — | — | 53.53 | 39.12 | 23.96 | -19.70 | -3.55 |
Short-term solvency ratios and asset-utilisation metrics
AbCellera Biologics Inc.'s current ratio of 11.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.33x to 11.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.32 | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | 1.60 | 2.36 |
| Quick Ratio | 11.32 | 11.32 | 9.81 | 7.32 | 8.65 | 7.69 | 7.85 | 1.58 | 2.36 |
| Cash Ratio | 8.30 | 8.30 | 8.17 | 6.39 | 7.49 | 5.99 | 5.74 | 0.96 | 1.62 |
| Asset Turnover | — | 0.12 | 0.02 | 0.03 | 0.32 | 0.28 | 0.23 | 0.49 | 0.41 |
| Inventory Turnover | — | — | — | — | 43.37 | 27.22 | 19.28 | — | — |
| Days Sales Outstanding | — | 283.21 | 1166.28 | 618.00 | 29.02 | 156.21 | 334.59 | 66.76 | 58.05 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AbCellera Biologics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 4.9% | 3.4% | 1.1% | — | — |
| FCF Yield | — | — | — | — | 6.4% | 4.1% | 0.1% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $299M | $294M | $289M | $315M | $318M | $263M | $238M | $151M |
Compare ABCL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ABCLYou | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| TECX | $439M | -6.0 | — | — | — | — | -206.6% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ABCL stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonAbCellera Biologics Inc.'s current P/E ratio is -7.4x. The historical average is 46.5x.
AbCellera Biologics Inc.'s return on equity (ROE) is -14.5%. The historical average is -0.0%.
Based on historical data, AbCellera Biologics Inc. is trading at a P/E of -7.4x. Compare with industry peers and growth rates for a complete picture.
AbCellera Biologics Inc. has -289.0% operating margin.